The sample size is the number of observational units included in a study or assigned to a specified study arm.
The statistical power of a test at an alternative parameter value is the probability that the test rejects its null hypothesis at that value.
A group sequential design analyzes accumulating data at prespecified interim analyses and may stop early for efficacy or futility.
A sequential stopping boundary specifies values of an accumulating test statistic that trigger early stopping for efficacy, futility, or harm.
At information levels , standardized efficient test statistics have unit variances, means proportional to , and correlations for .
A two-stage clinical trial design permits early stopping after an interim analysis for futility or efficacy and otherwise continues to a prespecified final decision boundary.
Neyman allocation assigns sample sizes in proportion to outcome standard deviations to minimize variance.
Response-adaptive randomization updates treatment probabilities using outcomes observed during a trial.
Articles by others on the same topic
A clinical trial is a research study conducted to evaluate the effects, efficacy, and safety of medical interventions, such as drugs, devices, therapies, or procedures, in humans. These trials are crucial for advancing medical knowledge and improving patient care. Clinical trials typically follow a structured protocol and are conducted in phases: 1. **Phase I**: Focuses on assessing the safety, dosage, and potential side effects of a new treatment in a small group of participants.